Bleeding Tendencies, Systemic Therapy

Products and indications for individuals with impaired bleeding tendencies#

Product	Description	Indication
Cryoprecipitate	Unit=150-250 mL F VIII, FXIII, vWF, fibrinogen	Hemophilia A; von Willebrand disease
DDAVP	0.3µg/kg IV or SQ Intranasal application	Active bleeding or prophylactically for von Willebrand disease
ε-Aminocaproic acid	Antifibrinolytic 25% oral solution (250 mg/mL) Systemic – 75 mg/kg q6h	Adjunct to support clot formation
F VIII concentrate	Unit raises F VIII level by 2%	Hemophilia A
F IX concentrate (PCC)	Unit raises F IX level by 1-1.5% F II, F VII, F IX and F X Monoclonal F IX	Hemophilia B; hemophilia A with inhibitor
FFP	Unit=150-250 mL F II, F VII, F IX, F XI, F XII, F XIII and heat-labile F V, and F VII	Undiagnosed bleeding disorder with active bleeding; severe liver disease; immune globulin deficiency
Tranexamic acid	Antifibrinolytic 4.8% oral solution Systemic – 25 mg/kg q8h	Adjunct to support clot formation
DDAVP=desmopressin; F=factor; IV=intravenously; FFP=fresh frozen plasma; PCC=prothrombin complex concentrate; SQ=subcutaneously; vWF=von Willebrand factor